EVIDENCE BASED USE OF ERYTRHOPOIETIN IN PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: A MULTICENTER INTERNATIONAL STUDY
Author(s): ,
Bruno Fattizzo
Affiliations:
Hematology,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano,Milan,Italy
,
Laetitia Languille
Affiliations:
Internal Medecine, national referral center for adult’immune cytopenias,Henri Mondor University Hospital,Paris,France
,
Giorgia Levati
Affiliations:
Ematologia,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,Milan,Italy
,
Francesca R Mauro
Affiliations:
Hematology,Department of Translational and Precision Medicine, Sapienza University,Rome,Italy
,
Bernd Jilma
Affiliations:
Medical University of Vienna,Vienna,Austria
,
Andrea Patriarca
Affiliations:
UO Ematologia,AOU Maggiore della Carità,Novara,Italy
,
Anita Hill
Affiliations:
Hematology,Leeds' Teaching Hospital,Leeds,United Kingdom
,
Sigbjorn Berentsen
Affiliations:
Department of Reseach and Innovation,Haugesund Hospital,Oslo,Norway
,
Marc Michel
Affiliations:
Department of Internal Medecine,Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris,Creteil,France
Wilma Barcellini
Affiliations:
Hematology,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano,Milan,Italy
EHA Library. Fattizzo B. Jun 15, 2019; 267483; S900
Dr. Bruno Fattizzo
Dr. Bruno Fattizzo
Contributions
×
Abstract

Abstract: S900

Type: Oral Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 16:15 - 16:30

Location: Hall G102

Background

Autoimmune hemolytic anemia (AIHA) is clinically heterogeneous, from chronic compensated to abrupt hemolysis. Together with the rate of antibody mediated erythrocyte destruction, bone marrow reticulocyte compensation is a recently recognized determinant of outcome. Erythropoietin (EPO) has been anecdotally used in AIHA to ameliorate bone marrow response, but only one systematic series has been published and predictors of response are not known

 

Aims

To evaluate EPO efficacy and its predictors in a cohort of AIHA patients

 

Methods

Data on primary and secondary AIHA cases who had received EPO either alone or concomitantly to other therapies were retrospectively collected using a preformed survey. Efficacy was evaluated at 15 and 30 days, and then at 3,6 and 12 months; Hb response was considered partial (PR, >2 g/dL Hb increase or >10g/dL) or complete (CR, >12g/dL) and hemolytic markers (LDH, reticulocytes) were registered

 

Results

29 AIHA cases followed from June 2007 to February 2019 at 7 centers in Italy, France, Norway, Austria, and UK were included in the study. Main AIHA types (warm, cold, mixed, and DAT negative) were present, and 3 cases were secondary to a lymphoproliferative disorder (not active and without specific treatment at the moment of the study). Patients’ characteristics are shown in table 1: at diagnosis 74% of cases presented with severe anemia and 95% displayed inadequate reticulocytosis (i.e. bone marrow responsiveness index<121). Bone marrow evaluation at diagnosis (N=16) showed hypercellularity with dyserythropoiesis in 7 cases, and reticulin fibrosis in 3; a lymphoid infiltrate was found in 13 patients (T-cell in 4, B-cell in 7, mixed in 2), greater than 10% in the 3 secondary cases only. All patients had received at least one previous therapy, and the majority (69%) started EPO because of non-response to ongoing treatment (steroids 15, immunosuppressor 4, sutimlimab 1). Six patients had received rituximab during the 3 months before EPO start (median 1 month, range 0-5). At EPO initiation, 21% of cases displayed severe anemia, 73% had inadequate reticulocytosis, and 89% (of 18 tested) showed inappropriately low endogenous EPO levels. Patients were treated for a median of 7 months and responses were observed in about 70% of cases at month+1 and +3 (table1), with a median Hb and reticulocyte increase of 21.5 (2-48) g/L (p<0.001) and 25(0-220)x109/L at month+1; and 29 (0-66) g/L (p<0.001) and 49 (0-195)x109/L at month+3, respectively. Notably, 64% of patients responded as soon as at day+15; this finding supports an activity of EPO although recent or concomitant treatments may have contributed. At last follow up, 13 cases had discontinued EPO: 6 for long standing CR and 7 because of NR (3 with hemolytic flares). We observed an association of response to EPO and primary AIHA (73 vs 33% in secondary), inadequate reticulocytosis (76 vs 50% with adequate reticulocytosis), and not-warm (85 vs 50% in warm cases) not transfusion dependent cases (76 vs 50% transfusion dependent), although the small number did not allow statistical significance

 

Conclusion

Use of EPO is effective in about 70% of AIHA patients unresponsive to ongoing/previous treatments, particularly in cases with inadequate reticulocytosis. Although preliminary, these data advise EPO use to stimulate bone marrow compensatory response

 

Session topic: 28. Enzymopathies, membranopathies and other anemias

Keyword(s): Autoimmune hemolytic anemia (AIHA), Bone marrow failure, Erythropoietin

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies